Eileen Peng, PharmD, discusses how her team has restructured pharmacy services to support outpatient administration of CAR T-cell and bispecific therapies—emphasizing multidisciplinary collaboration, early toxicity management, real-world data integration, and pharmacist-led care transitions to ensure safety and continuity across care settings.